Dublin, Feb. 18, 2026 (GLOBE NEWSWIRE) -- The "Monkeypox - Competitive Landscape, 2026" has been added to ResearchAndMarkets.com's offering.
The "Monkeypox - Competitive Landscape, 2026" report offers extensive insights into myriad companies and drugs within the Monkeypox competitive sphere, focusing on therapeutics evaluated by product type, development stage, administration route, and molecule type. This analysis includes a detailed review of active and inactive pipeline products.
Mpox, previously called monkeypox, is a virulent disease propagated by the monkeypox virus, a member of the Orthopoxvirus genus. It originated in Central and West Africa but expanded globally since 2022, affecting regions such as the United States and Europe. Transmission occurs through close interaction with infected individuals or fauna, presenting symptoms between 3 to 17 days post-exposure. The illness typically persists 2 to 4 weeks, with common indicators including a painful rash, fever, and swollen lymph nodes. Effective mitigation relies heavily on smallpox vaccinations and public health protocols.
Report Highlights:
- In September 2024, TC BioPharm announced plans to commence preclinical studies for TCB 008, targeting monkeypox treatment.
- Tonix Pharmaceuticals revealed its TNX-801 Mpox Vaccine Candidate aligns with WHO's target profile for global health emergencies.
- Preliminary results from the NIH's PALM 007 clinical trials on SIGA's tecovirimat were released in August 2024.
- Emergent BioSolutions received FDA approval for expanding ACAM2000's use in high-risk individuals.
- Bavarian Nordic submitted IMVANEX data for regulatory extension to cover adolescents aged 12-17.
Company and Product Profiles (Marketed Therapies):
- Bavarian Nordic: A leading entity in vaccine innovation, Bavarian Nordic is recognized globally for its smallpox and mpox vaccines, vital to public health readiness.
- Product: MVA-BN is a non-replicating smallpox vaccine known as JYNNEOS in the US, offering broad coverage during the 2022-2023 outbreak.
Pipeline Therapies:
- Moderna Therapeutics: Specializes in mRNA-based therapies, with a strong pipeline aiming at monkeypox prevention.
- Product: mRNA-1769, in clinical trials for monkeypox, enhances the immune system to block viral infections.
- BioNTech: An innovator in immunotherapies, BioNTech develops advanced therapeutics for various diseases.
- Product: BNT166a, an mRNA vaccine under Phase I/II trials, seeks to counter monkeypox through targeted immune responses.
Monkeypox Analytical Perspective
Monkeypox Report Assessment:
- Company Analysis
- Therapeutic Assessment
- Pipeline Assessment
- Inactive Drugs Assessment
- Unmet Needs
Key Players and Products:
- Bavarian Nordic - Modified vaccinia Ankara
- BioNTech - BNT166a
- Moderna Therapeutics - mRNA-1769
- Tonix Pharmaceuticals - TNX-801
- Emergent BioSolutions - ACAM2000
For more information about this report visit https://www.researchandmarkets.com/r/iln67
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
